Cite
HARVARD Citation
Arkenau, H. et al. (2018). An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European journal of cancer. pp. 17-23. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Arkenau, H. et al. (2018). An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European journal of cancer. pp. 17-23. [Online].